clinical trial · NCT07601074
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
Daré Bioscience, Inc.·phase2·not yet recruiting·n = 118
Human Papilloma Virus (HPV)High-risk Human Papillomavirus InfectionLopinavir / ritonavir
brief summary
The goal of this clinical study is to learn if DARE-HPV can treat persistent high-risk human papillomavirus (hrHPV). The primary outcome will be if the genital infection clears following treatment in 30, 60 or 90 days. The study will look at two different doses of DARE-HPV and two different treatment durations of 14 and 21 days compared to a placebo group or 14 or 21 days of treatment.
started
Jun 1, 2026
primary completion
Oct 1, 2027
completion
Dec 1, 2027
last updated
Jun 2, 2026
official title
A Phase 2a, Multi-Center, Placebo-Controlled, Double-Blinded, Randomized, Dose Ranging Study of the Preliminary Efficacy of DARE-HPV to Treat Persistent High-Risk Human Papillomavirus (HPV) Genital Infection
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol